Sex: F
Vaccine: RAB
Symptoms: Extra dose administered, Lack of vaccination site rotation
Clinical narrative: The patient went to the emergency room (ER) and they administered the RabAvert in the same arm muscle as the Immunoglobulin shot next to each other; It was an administration error; The second dose of RabAvert was given one day after the first dose in case the first one was not effective.; Case reference number US-BN-2023-010734 is a spontaneous case report initially received from a consumer via agency (reference number: USBAV23-2174) on 26-Dec-2023 and concerns an adult female patient.  The patient's medical history and concomitant medication details were not provided.  On an unspecified date in Nov-2023, the patent had a bat exposure.   On 09-Nov-2023, an unknown amount of time after the animal exposure, the patient was vaccinated with the first dose of RabAvert (batch number: ARBB101A, expiry date: 01-Jan-2026) at unknown dose, intramuscularly, in unknown site of administration for post-exposure to rabies with co-suspect imunoglobulin vaccine (brand name unknown, batch number unknown) administered in the same arm muscle as the RabAvert vaccine next to each other, at an unknown dose or route of administration and for unknown indication (explicitly coded as 'lack of vaccination site rotation').  On 10-Nov-2023, unknown amount of time after the animal exposure, the patient was vaccinated with the second dose of RabAvert (batch number: ARBB101A, expiry date: 01-Jan-2026) at unknown dose, intramuscularly, in unknown site of administration. As reported, the second dose of RabAvert was given one day after the first dose in case the first one was not effective and it was an administration error (explicitly coded as 'extra dose administered' and 'product administration error').  On 13-Nov-2023, unknown amount of time after the animal exposure, the patient was vaccinated with the third dose of RabAvert (batch number: ARBB101A, expiry date: 01-Jan-2026) at unknown dose, intramuscularly, in unknown site of administration.  On 17-Nov-2023, unknown amount of time after the animal exposure, the patient was vaccinated with the fourth dose of RabAvert (batch number: ARBB101A, expiry date: 01-Jan-2026) at unknown dose, intramuscularly, in unknown site of administration.  On 25-Nov-2023, unknown amount of time after the animal exposure, the patient was vaccinated with the fifth dose of RabAvert (batch number: ARBA971A, expiry date: 01-Feb-2025) at unknown dose, intramuscularly, in unknown site of administration.  On 12-Dec-2023, unknown amount of time after the animal exposure, the patient was vaccinated with the fifth booster dose of RabAvert (batch number: YRBA821A expiry date: 29-Feb-2024) at unknown dose, intramuscularly, in unknown site of administration.  At the time of the initial report, it was unknown if the patient experienced any adverse event due to RabAvert vaccine.  No further information was provided.  Additional information received on 27-Dec-2023 from a consumer via Bavarian Nordic included confirmation that the patient thought it was related to the active product and not the water for injection.; Reporter's Comments: An adult female patient was vaccinated with the first dose of RabAvert, at unknown dose, intramuscularly, in unknown site of administration for post-exposure to rabies with co-suspect imunoglobulin vaccine, administered in the same arm muscle, which is considered as lack of vaccination site rotation. The patient was vaccinated with the second dose of RabAvert on the following day, at unknown dose, intramuscularly, reportedly in case the first one was not effective and it was an administration error, which is considered as extra dose administered and product administration error. No associated adverse events were reported. Product administration error, extra dose administered and lack of vaccination site rotation are listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error, extra dose administered and lack of vaccination site rotation are not related to RabAvert, but to a human factor. The case is non-serious.; Sender's Comments: An adult female patient was vaccinated with the first dose of RabAvert, at unknown dose, intramuscularly, in unknown site of administration for post-exposure to rabies with co-suspect imunoglobulin vaccine, administered in the same arm muscle, which is considered as lack of vaccination site rotation. The patient was vaccinated with the second dose of RabAvert on the following day, at unknown dose, intramuscularly, reportedly in case the first one was not effective and it was an administration error, which is considered as extra dose administered and product administration error. No associated adverse events were reported. Product administration error, extra dose administered and lack of vaccination site rotation are listed per company convention. The patient's medical history and concomitant medication details were not provided. Product administration error, extra dose administered and lack of vaccination site rotation are not related to RabAvert, but to a human factor. The case is non-serious.